Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Corbus Pharmaceuticals Holdings, Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Last trade $2.99
Day change -$0.385 (-11.41%)
Day range $2.96 – $3.50
Volume 361,697
Market cap $70M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$69.65M
Price / earnings
—
Price / book
0.82×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.33×

Profitability

Earnings per share
-$5.64
Return on assets
-94.64%
Return on equity
-137.23%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
3.4×
Quick ratio
3.4×
Cash ratio
0.86×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$92.39M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for CRBP, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$4.58M$5.02M$4.49M$3.56M$3.56M$3.97M$4.13M$3.82M
Research and development$34.25M$31.18M$19.82M$18.41M$20.86M$15.19M$15.64M$8.79M
Total operating expenses$38.82M$36.19M$24.3M$21.97M$24.42M$19.15M$19.78M$12.61M
Operating income-$38.82M-$36.19M-$24.3M-$21.97M-$24.42M-$19.15M-$19.78M-$12.61M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$37.75M-$35.04M-$22.97M-$20.56M-$23.34M-$17.66M-$16.98M-$9.53M
Income taxes$0$0$0$0$0$0$0$0
Net income-$37.75M-$35.04M-$22.97M-$20.56M-$23.34M-$17.66M-$16.98M-$9.53M
Net income attributable to common shareholders-$37.75M-$35.04M-$22.97M-$20.56M-$23.34M-$17.66M-$16.98M-$9.53M
EBITDA-$38.77M-$36.14M-$24.26M-$21.92M-$24.37M-$19.1M-$19.69M-$12.47M
Basic earnings per share-$1.81-$1.81-$1.23-$1.24-$1.90-$1.44-$1.39-$0.78
Diluted earnings per share-$1.81-$1.81-$1.23-$1.24-$1.90-$1.44-$1.39-$0.78

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Corbus Pharmaceuticals to Participate in Upcoming Investor Conferences

Corbus Pharmaceuticals announced that CEO Yuval Cohen will present a corporate overview and participate in investor meetings at the RBC Capital Markets Global Healthcare Conference (May 19-20, 2026) and the Jefferies Global Healthcare Conference (June 2-4, 2026). The clinical-stage company is developing CRB-701, an antibody drug conjugate for Nectin-4-expressing tumors, and CRB-913, an obesity treatment candidate.

GlobeNewswire Inc.

Corbus Pharmaceuticals Reports Q1 2026 Financial Results and Provides a Corporate Update

Corbus Pharmaceuticals announced FDA alignment on the registration path for CRB-701 in head and neck squamous cell carcinoma and cervical cancer, with a registrational study expected to launch this summer. The company completed enrollment in its CANYON-1 Phase 1b study of CRB-913 for obesity treatment with topline data expected summer 2026. Q1 2026 net loss was $23.0 million with $138.2 million in cash expected to fund operations into 2028.

GlobeNewswire Inc.

Corbus Pharmaceuticals to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage oncology and obesity company, announced that CEO Yuval Cohen will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026. The company's pipeline includes CRB-701 (antibody drug conjugate), CRB-601 (anti-integrin monoclonal antibody), and CRB-913 (CB1 inverse agonist for obesity treatment), which recently demonstrated a favorable safety profile and emerging evidence of weight loss in Phase 1a studies.

GlobeNewswire Inc.

Corbus Pharmaceuticals Announces Pricing of Public Offering

Corbus Pharmaceuticals plans to raise approximately $75 million through a public offering of 4,744,231 common stock shares and pre-funded warrants, with proceeds intended to fund clinical development and working capital.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Feb 14, 20231-for-30reverse split